Pediatric Malignant Hyperthermia Recognition: A Critical Skill for Anesthesiologists

What Pediatric Malignant Hyperthermia Is

Malignant hyperthermia (MH) is a rare but potentially fatal disorder that can occur during general anesthesia. It results from a genetic defect in the skeletal muscle, leading to an abnormal response to certain triggering agents such as succinylcholine and halothane. In children undergoing anesthesia, MH can be particularly dangerous due to their smaller body size and higher metabolic rate.

The condition is characterized by a rapid increase in body temperature, muscle rigidity, tachycardia, hypotension, and acidosis. Early recognition and prompt treatment are crucial for preventing organ failure and death.

Why It Happens

Malignant hyperthermia is caused by a mutation in the ryanodine receptor (RyR1) protein, which regulates calcium release from the sarcoplasmic reticulum in muscle cells. When triggered by anesthetic agents or other stressors like heat, this leads to excessive calcium influx into muscle fibers, causing uncontrolled contraction and increased metabolic activity.

The condition is inherited as an autosomal dominant trait, meaning that a single copy of the mutated gene from one parent is sufficient for a child to be at risk. However, only about 1 in 4000 individuals carry this mutation.

Signs and Symptoms

The signs and symptoms of malignant hyperthermia can be subtle or severe, making early recognition challenging. Common indicators include tachycardia, hypertension, muscle rigidity, flushing, diaphoresis, and an increase in body temperature (hyperthermia). Other less common signs may include hyperventilation, rhabdomyolysis, and metabolic acidosis.

Prompt identification is critical because the condition can progress rapidly. If left untreated, it can lead to multi-organ failure and death.

Diagnosis and Management

Diagnosing malignant hyperthermia requires a combination of clinical suspicion, laboratory tests, and specific diagnostic tools such as the caffeine halothane contracture test (CHCT). This test involves injecting a small amount of caffeine and halothane into a muscle biopsy to observe whether there is an exaggerated contraction response.

Once diagnosed, immediate treatment with intravenous dantrolene sodium is essential. Cooling measures are also critical to reduce body temperature and prevent further metabolic complications.

Frequently asked questions

Try it live

Everything above runs in your browser — open Pediatric Malignant Hyperthermia Recognition and change the parameters while it is running. Nothing is installed, nothing is uploaded, the whole model lives in one tab.